Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00076934 | Safety of RG2077 in Patients With Multiple Sclerosis | PHASE1 | COMPLETED | 20 | — | — | Jan 1, 2003 | Feb 1, 2006 | Mar 27, 2017 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Participants receive Regimen 1 for 4 months |
| 2 | EXPERIMENTAL | Participants receive Regimen 2 for 4 months |
| 3 | EXPERIMENTAL | Participants receive Regimen 3 for 4 months |
| 4 | EXPERIMENTAL | Participants receive Regimen 4 for 4 months |
| Name | Type | Description |
|---|---|---|
| RG2077 (CTLA4-IgG4m) | DRUG | RG2077 |
Inclusion Criteria * Confirmed diagnosis of MS, defined as an MRI consistent with MS plus two separate clinical events, or one clinical event and MRI consistent with demyelination plus a second MRI demonstrating new lesions * Have declined all FDA approved therapies for MS